1. Agrawal, S., 2003. Biopharmaceutics and pharmacokinetics of rifampicin: implications in performance and evaluation of anti-tuberculosis fixed dose combination formulations. PhD thesis, submitted at National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, India.
2. Agrawal, S., Panchagnula, R., 2004. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms. Die Pharmazie, in press.
3. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm. Res.,1995
4. Blomberg, B., Evans, P., Phanouvong, S., Nunn, P., 2002. Informal consultation on 4-drug fixed dose combinations (4FDCs) compliant with the WHO model list of essential drugs. World Health Organization, Geneva, WHO/CDS/TB/2002.299, 15–17 August 2001.
5. Solid state nuclear magnetic resonance spectroscopy: theory and pharmaceutical applications;Bugay;Pharm. Res.,1993